Array Biopharma, Inc. (ARRY) Reports Q1 EPS Loss of $0.06, Sales Beat Expectations
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $8.58 +7.25%
EPS Growth %: -48.0%
Financial Fact:
Interest income: 70K
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -48.0%
Financial Fact:
Interest income: 70K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q1 EPS of ($0.06), $0.13 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $22.1 million versus the consensus estimate of $17.38 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ARRAY Technologies Launches DuraTrack D2S™ Tracker, Bringing Differentiated Features of ARRAY’s Trusted DuraTrack System to Dual Row Format Internationally
- Kroger meets earnings expectations, revenue tops estimates
- CarMax beats estimates as new strategy drives early results
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
